The LRRK1/2-selective type II inhibitors RN277 and RN341 represent a new set of tool compounds, which will open avenues for therapeutic development for PD and that harbor substantial research potential for uncovering the broader impact of using conformation-specific LRRK2 inhibitors in vivo and in cells. The gene discussed is LRRK1; the disease is Parkinson disease.